News > Roche Pharma launches Multiple Sclerosis treatment drug in India

Roche Pharma launches Multiple Sclerosis treatment drug in India

Roche Pharma India introduced Ocrevus (Ocrelizumab) which is the first and only approved disease-modifying therapy for both Relapsing-Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS). Patients on Ocrevus have the highest persistence and superior adherence to treatment because of its twice-yearly (once every six months) dosing which is preferable for most patients compared to more frequent (monthly) injections.